Lipoprotein(a): Science, Evidence, Management and Emerging Therapies (Optional/Not for Credit)

Residual ASCVD Risk & Other Players in Dyslipidemia (Optional/Not for Credit)

  • Lipoprotein(a): Science, Evidence, Management and Emerging Therapies
    • Lipoprotein (a): Prevalence, Pathophysiology, and Role in ASCVD Risk
    • Lp(a): Testing and Current Role in Guidelines and Risk Assessment
    • Current Treatment Options for Lp(a)
    • Emerging Therapeutic Options for Lp(a)
    • Lp(a) Patient Case Study

Additional Information

AttachmentSize
PDF icon Non-CME Presentation Slides: Module 5 - Lipid Management: Lipoprotein(a)- Science, Evidence, Management and Emerging Therapies4.61 MB
PDF icon Non-CME Transcription: Module 5 - Lipid Management: Lipoprotein(a)- Science, Evidence, Management and Emerging Therapies260.28 KB
Course summary
Course opens: 
03/11/2022
Course expires: 
06/24/2025
Part of: 
Module 5: Lipid Management
Rating: 
5

Sotirios Tsimikas, MD 
Director of Vascular Medicine
Professor of Medicine
University of California San Diego

Dr. Tsimikas discloses the following: 
Salary: Ionis
Royalty/Receipt of Intellectual Property Rights/Patent Holder: UCSD
Consulting/Contracted Research: Novartis
Stockholder: Kleanthi Dx, Oxitope Inc, Covicept Therapeutics

Please login or register to take this course.